AbbVie (ABBV) Maintains Immunology Dominance as Analysts Downplay Competitive Threat From J&J’s Tremfya to Skyrizi Market Share
AbbVie Inc. (NYSE:ABBV) is one of the best stocks for the next decade.
Abbvie Inc. (ABBV)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 3,105,426 | $719,030,336 | -5% | 0.11% |
| 2. | 2,409,100 | $557,803,014 | +7% | 0.08% | |
| 3. | Millennium Management Israel Englander | 2,015,742 | $466,724,903 | -18% | 0.2% |
| 4. | 1,889,200 | $437,425,368 | +53% | 0.07% | |
| 5. | Adage Capital Management Phill Gross And Robert Atchinson | 1,844,792 | $427,143,140 | +14% | 0.68% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $69.00 | 1,550 | $106,950.00 | 17,644 | 2020-03-20 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-20 | Filing | |
| $67.50 | 800 | $54,000.00 | 16,094 | 2020-03-20 | Filing | |
| $68.18 | 2,200 | $150,004.80 | 15,294 | 2020-03-18 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $198.42 | 42,370 | $8,407,055.40 | 177,292 | 2025-08-12 | Filing | |
| $198.59 | 10,061 | $1,998,013.99 | 58,247 | 2025-08-05 | Filing | |
| $198.27 | 3,234 | $641,238.89 | 68,308 | 2025-08-05 | Filing | |
| $210.54 | 33,132 | $6,975,611.28 | 53,234 | 2025-03-31 | Filing | |
| $209.49 | 25,700 | $5,383,893.00 | 86,366 | 2025-03-31 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 443,006 | $95,347,866 | 1.13% | |
| 2. | 99,596 | $22,756,690 | 0.71% | |
| 3. | 60,735 | $13,877,453 | 0.7% | |
| 4. | 51,082 | $11,671,670 | 4.35% | |
| 5. | 50,580 | $11,557,133 | 0.36% |
News See All
BofA Cuts AbbVie (ABBV) Target While Maintaining Neutral View
On December 15, BofA lowered the firm’s price target on AbbVie Inc. (NYSE:ABBV) to $233 from $248 and kept a Neutral rating.
14 Best Pharma Dividend Stocks to Buy in 2026
For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other developed countries. Branded medicines carry even steeper premiums.
Long-Term Stock Portfolio: 10 Best Stocks for the Next Decade
On December 16, Julian Emanuel, Senior Managing Director at Evercore ISI, shared his outlook on the equity market and the ongoing influence of AI.
Analysts Split on AbbVie Inc. (ABBV) as BofA Cuts Target and HSBC Turns Bullish
TheFly reported on December 15 that Bank of America (BofA) lowered its price target for ABBV to $233 from $248 while maintaining a Neutral rating, reflecting a modestly reduced valuation outlook even ...
9 Most Undervalued Pharma Stocks to Buy Right Now
The U.S. pharmaceutical industry in 2025 remains one of the nation’s most dynamic and profitable economic sectors.
HSBC Upgrades AbbVie (ABBV) to Buy, Raises Price Target to $265
On December 10, HSBC increased its price target on AbbVie Inc. (NYSE:ABBV) from $225 to $265 and also upgraded the stock to Buy.
15 Best Stocks to Buy for the Long Term
Dividend stocks offer solid investment options when it comes to long-term investing.
AbbVie (ABBV) Surged Following Strong Results and Increased Guidance
Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Growth & Income Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Piper Sandler Raises AbbVie (ABBV) Price Target to $289, Maintains Overweight Rating
On November 5, Piper Sandler analyst David Amsellem raised the price target on AbbVie Inc.
Hedge Fund Resource Center Billionaire Hedge Funds
